Late‐life mood disorder as the initial presentation of progressive supranuclear palsy: A case series
Kei Ichijo,
Keisuke Takahata,
Shin Kurose,
Takemi Watanabe,
Yukihiro Nagase,
Hironobu Endo,
Kenji Tagai,
Makoto Ishitobi,
Makoto Higuchi
Affiliations
Kei Ichijo
Takatsuki Hospital Hachioji Tokyo Japan
Keisuke Takahata
Department of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan
Shin Kurose
Department of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan
Takemi Watanabe
Takatsuki Hospital Hachioji Tokyo Japan
Yukihiro Nagase
Takatsuki Hospital Hachioji Tokyo Japan
Hironobu Endo
Department of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan
Kenji Tagai
Department of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan
Makoto Ishitobi
Jinkei Hospital Himeji Hyogo Japan
Makoto Higuchi
Department of Functional Brain Imaging, Institute for Quantum Medical Science, Quantum Life and Medical Science Directorate National Institutes for Quantum Science and Technology Inage Chiba Japan
Abstract Aim Progressive supranuclear palsy (PSP) is a rapidly progressive neurodegenerative disorder characterized by Parkinsonism, supranuclear ophthalmoplegia, postural instability, and cognitive impairment. Patients This case series describes three patients initially diagnosed with late‐life mood disorders (depression and bipolar disorder) who were later diagnosed with PSP because of the development of typical neurological symptoms. Result The diagnostic challenge of PSP is highlighted in this case report, particularly in the early stages, when characteristic symptoms may not be present. The importance of considering PSP in the differential diagnosis of late‐life mood disorders, especially in the absence of response to standard antidepressant therapy, is also emphasized. The heterogeneity of PSP is described, with various subtypes and atypical variants presenting with different clinical features. The psychiatric symptoms of PSP include apathy, disinhibition, depression, and anxiety, whereas hallucinations and delusions are less frequent. Tau positron emission tomography imaging is discussed as a potential biomarker for atypical PSP. Conclusion Early diagnosis and intervention are crucial for improved outcomes in PSP, necessitating further research to enhance the diagnostic and treatment strategies for PSP and other neurodegenerative diseases.